Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRA | P16234 | 5/20 | 0.68 |
| ▸ | KDR | P35968 | 4/20 | 0.68 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.65 |
| ▸ | MET | P08581 | 4/20 | 0.63 |
| ▸ | FGFR2 | P21802 | 4/20 | 0.62 |
| ▸ | AURKA | O14965 | 1/20 | 0.61 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.61 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.61 |
| ▸ | ABL1 | P00519 | 1/20 | 0.61 |
| ▸ | EGFR | P00533 | 1/20 | 0.61 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.61 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.61 |
| ▸ | LCK | P06239 | 1/20 | 0.61 |
| ▸ | PGR | P06401 | 1/20 | 0.61 |
| ▸ | LYN | P07948 | 1/20 | 0.61 |
| ▸ | RET | P07949 | 1/20 | 0.61 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.61 |
| ▸ | HCK | P08631 | 1/20 | 0.61 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.61 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluorobenzene SCHEMBL28724473 | 0.94 | FGFR2 (0.65) | PDGFRAKDRPDGFRBMETFGFR2 | |
| SCHEMBL167396 | 0.93 | PDGFRA (0.74) | PDGFRAKDRPDGFRBFGFR2EGFR | |
| Hydrochloric Acid SCHEMBL23528156 | 0.92 | PDGFRA (0.72) | PDGFRAKDRPDGFRBFGFR2EGFR | |
| SCHEMBL282174 | 0.88 | PDGFRA (0.59) | PDGFRAKDRPDGFRBMETFGFR2 | |
| SCHEMBL4471141 | 0.86 | FGFR2 (0.83) | PDGFRAKDRPDGFRBMETFGFR2 | |
| SCHEMBL5825496 | 0.86 | PDGFRA (0.67) | PDGFRAKDRPDGFRBMETFGFR2 | |
| SCHEMBL14540576 | 0.85 | PDGFRA (0.62) | PDGFRAKDRPDGFRBFGFR2EGFR | |
| SCHEMBL13980801 | 0.84 | PDGFRA (0.60) | PDGFRAKDRPDGFRBFGFR2EGFR | |
| SCHEMBL14139343 | 0.84 | PDGFRA (0.61) | PDGFRAKDRPDGFRBFGFR2AXL | |
| SCHEMBL14139303 | 0.84 | PDGFRA (0.61) | PDGFRAKDRPDGFRBFGFR2AXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 149 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12016854-B2 | Liquid dosage forms to treat cancer | EXELIXIS, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-20240189298-A1 | PROCESSES FOR PREPARING QUINOLINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH COMPOUNDS | EXELIXIS, INC. | 2024-06-13 | — | — | US | disclosed |
| US-20240156804-A1 | C-Met Modulator Pharmaceutical Compositions | EXELIXIS, INC. | 2024-05-16 | — | — | US | disclosed |
| US-20240156803-A1 | Method of Treating Cancer | REGENTS OF THE UNIVERSITY OF MICHIGAN | 2024-05-16 | — | — | US | disclosed |
| US-11969419-B2 | Method of treating cancer | EXELIXIS, INC. (US) | 2024-04-30 | — | — | US | disclosed |
| CN-117771363-A | Carbotinib and alemtuzumab combination for treating cancer | 埃克塞里艾克西斯公司 | 2024-03-29 | — | — | CN | disclosed |
| CN-117205312-A | Carbotinib and alemtuzumab combination for treating cancer | 埃克塞里艾克西斯公司 | 2023-12-12 | — | — | CN | disclosed |
| CN-117205313-A | Carbotinib and alemtuzumab combination for treating cancer | 埃克塞里艾克西斯公司 | 2023-12-12 | — | — | CN | disclosed |
| US-20230314440-A1 | METHOD OF TREATING CANCER | EXELIXIS, INC. | 2023-10-05 | — | — | US | disclosed |
| US-20230301980-A1 | Method of Treating Cancer | EXELIXIS, INC. | 2023-09-28 | — | — | US | disclosed |
| WO-2013043840-A1 | METHOD FOR TREATING OSTEOPOROSIS | EXELIXIS, INC. (US) | 2013-03-28 | — | — | WO | disclosed |
| EP-2387563-B1 | MALATE SALT OF N- (4- { [ 6, 7-BIS (METHYLOXY) QUINOLIN-4-YL]OXY}PHENYL-N' - (4 -FLUOROPHENYL) CYCLOPROPANE-1,1-DICARBOXAMIDE, AND CRYSTALLINE FORMS THEREOF FOR THE TREATMENT OF CANCER | EXELIXIS INC (US) | 2013-03-06 | — | — | EP | disclosed |
| US-20120282179-A1 | Methods of Using C-Met Modulators | EXELIXIS, INC. (US) | 2012-11-08 | — | — | US | disclosed |
| US-20120252840-A1 | Method of Treating Cancer | EXELIXIS, INC. (US) | 2012-10-04 | — | — | US | disclosed |
| WO-2012109510-A1 | PROCESSES FOR PREPARING QUINOLINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH COMPOUNDS | EXELIXIS, INC. (US) | 2012-08-16 | — | — | WO | disclosed |
| EP-2461810-A1 | METHODS OF USING C-MET MODULATORS | Exelixis, Inc. (US) | 2012-06-13 | — | — | EP | disclosed |
| WO-2012044572-A1 | DUAL INHIBITORS OF MET AND VEGF FOR THE TREATMENT OF CASTRATION- RESISTANT PROSTATE CANCER AND OSTEOBLASTIC BONE METASTASES | EXELIXIS, INC. (US) | 2012-04-05 | — | — | WO | disclosed |
| WO-2012044577-A1 | DUAL INHIBITORS OF MET AND VEGF FOR THE TREATMENT OF CASTRATION RESISTANT PROSTATE CANCER AND OSTEOBLASTIC BONE METASTASES | EXELIXIS, INC. (US) | 2012-04-05 | — | — | WO | disclosed |
| WO-2012009722-A1 | C-MET MODULATOR PHARMACEUTICAL COMPOSITIONS | EXELIXIS, INC. (US) | 2012-01-19 | — | — | WO | disclosed |
| WO-2010083414-A1 | MALATE SALT OF N- (4- { [ 6, 7-BIS (METHYLOXY) QUIN0LIN-4-YL] OXY}PHENYL-N' - (4 -FLUOROPHENYL) CYCLOPROPANE-1-DICARBOXAMIDE, AND CRYSTALLINE FORMS THEROF FOR THE TREATMENT OF CANCER | EXELIXIS, INC. (US) | 2010-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11969419-B2 | Method of treating cancer | MET, HGF, ACP3 | PDGFRA 109/4885KDR 8/4885PDGFRB 70/4885 |
| US-20240156803-A1 | Method of Treating Cancer | MET, HGF, ACP3 | PDGFRA 109/4885KDR 8/4885PDGFRB 70/4885 |
| US-20230301980-A1 | Method of Treating Cancer | MET, HGF, ACP3 | PDGFRA 109/4885KDR 8/4885PDGFRB 70/4885 |
| US-20240156804-A1 | C-Met Modulator Pharmaceutical Compositions | MET, HGFAC, HGF | PDGFRA 143/4885KDR 191/4885PDGFRB 39/4885 |
| US-20240189298-A1 | PROCESSES FOR PREPARING QUINOLINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH COMPOUNDS | HAX1, HRH1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | PDGFRA 3965/4885KDR 4574/4885PDGFRB 3177/4885 |
| US-20120282179-A1 | Methods of Using C-Met Modulators | MET, KRAS, HGF | PDGFRA 174/4885KDR 157/4885PDGFRB 84/4885 |
| US-20120252840-A1 | Method of Treating Cancer | MET, FLT1, TIE1 | PDGFRA 209/4885KDR 4/4885PDGFRB 191/4885 |
| US-12016854-B2 | Liquid dosage forms to treat cancer | FGFR3, KRAS, TP53 | PDGFRA 299/4885KDR 164/4885PDGFRB 152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.